{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:02:30Z","timestamp":1774620150626,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1097\/md.0000000000000300","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T18:48:02Z","timestamp":1420742882000},"page":"e300","source":"Crossref","is-referenced-by-count":36,"title":["Long-Term Prognosis of Adult Patients with Steroid-Dependent Minimal Change Nephrotic Syndrome Following Rituximab Treatment"],"prefix":"10.1097","volume":"93","author":[{"given":"Yuko","family":"Iwabuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyo","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210309","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1046\/j.1523-1755.1999.07002.x","article-title":"Management of minimal lesion glomerulonephritis: evidence-based recommendations","volume":"70","author":"Bargman","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"R2-18-20210309","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1046\/j.1523-1755.2002.00303.x","article-title":"Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome","volume":"61","author":"Iijima","year":"2002","journal-title":"Kidney Int"},{"key":"R3-18-20210309","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-007-0709-6","article-title":"Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: longterm treatment up to 10 years","volume":"23","author":"Kranz","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R4-18-20210309","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","article-title":"Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases","volume":"23","author":"Guigonis","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R5-18-20210309","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","article-title":"Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children","volume":"24","author":"Kamei","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R6-18-20210309","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/ndt\/gfm128","article-title":"Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?","volume":"22","author":"Hofstra","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R7-18-20210309","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.ajkd.2006.10.015","article-title":"Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations","volume":"49","author":"Fran\u00e7ois","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R8-18-20210309","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1056\/NEJMc063706","article-title":"Rituximab in patients with the steroid-resistant nephrotic syndrome","volume":"356","author":"Bagga","year":"2007","journal-title":"N Engl J Med"},{"key":"R9-18-20210309","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","article-title":"Rituximab efficiency in children with steroid-dependent nephrotic syndrome","volume":"25","author":"Sellier-Leclerc","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R10-18-20210309","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R11-18-20210309","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","article-title":"Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine","volume":"25","author":"Fujinaga","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R12-18-20210309","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-18-20210309","first-page":"60541","article-title":"On behalf of the Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"S0140-6736","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"R14-18-20210309","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","article-title":"Effect of single-dose rituximab on steroid-dependent minimal change nephrotic syndrome in adults","volume":"28","author":"Takei","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R15-18-20210309","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2005.04.004","article-title":"CD20: a target antigen for immunotherapy of autoimmune diseases","volume":"4","author":"Perosa","year":"2005","journal-title":"Autoimmun Rev"},{"key":"R16-18-20210309","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"key":"R17-18-20210309","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/ndt\/gft312","article-title":"Rituximab for minimal change disease in adults: long-term follow-up","volume":"29","author":"Bruchfeld","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R18-18-20210309","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R19-18-20210309","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (RIT) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"R20-18-20210309","first-page":"139","article-title":"Improving Global Outcomes (KDIGO). Glomerulonephritis Work Group KDIGO Clinical Practice Guideline for Glomerulonephritis.","volume":"2","author":"Kidney","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"R21-18-20210309","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5414\/CN107187","article-title":"GSTT1 gene abnormality in minimal change nephrotic syndrome with elevated serum immunoglobulin E","volume":"77","author":"Miyazaki","year":"2012","journal-title":"Clin Nephrol"},{"key":"R22-18-20210309","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R23-18-20210309","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000000300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:39:12Z","timestamp":1620959952000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201412040-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":23,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000300","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}